RU2528884C2 - Лечение опухолей с помощью антитела к vegf - Google Patents

Лечение опухолей с помощью антитела к vegf Download PDF

Info

Publication number
RU2528884C2
RU2528884C2 RU2009110102/15A RU2009110102A RU2528884C2 RU 2528884 C2 RU2528884 C2 RU 2528884C2 RU 2009110102/15 A RU2009110102/15 A RU 2009110102/15A RU 2009110102 A RU2009110102 A RU 2009110102A RU 2528884 C2 RU2528884 C2 RU 2528884C2
Authority
RU
Russia
Prior art keywords
her2
antibody
cancer
treatment
vegf
Prior art date
Application number
RU2009110102/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2009110102A (ru
Inventor
ФРИСС Томас
ХАСМАНН Макс
ШОЙЕР Вернер
Original Assignee
Ф.Хоффманн-Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37607207&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2528884(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ф.Хоффманн-Ля Рош Аг filed Critical Ф.Хоффманн-Ля Рош Аг
Publication of RU2009110102A publication Critical patent/RU2009110102A/ru
Application granted granted Critical
Publication of RU2528884C2 publication Critical patent/RU2528884C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
RU2009110102/15A 2006-08-21 2007-08-17 Лечение опухолей с помощью антитела к vegf RU2528884C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06017330.9 2006-08-21
EP06017330 2006-08-21
PCT/EP2007/007276 WO2008022746A1 (en) 2006-08-21 2007-08-17 Tumor therapy with an anti-vegf antibody

Publications (2)

Publication Number Publication Date
RU2009110102A RU2009110102A (ru) 2010-09-27
RU2528884C2 true RU2528884C2 (ru) 2014-09-20

Family

ID=37607207

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2009110102/15A RU2528884C2 (ru) 2006-08-21 2007-08-17 Лечение опухолей с помощью антитела к vegf

Country Status (28)

Country Link
US (6) US20080050385A1 (https=)
EP (2) EP2441472B1 (https=)
JP (3) JP2010501498A (https=)
KR (1) KR101136763B1 (https=)
CN (1) CN101505792B (https=)
AR (1) AR062419A1 (https=)
AU (1) AU2007287794B2 (https=)
BR (1) BRPI0715829A2 (https=)
CA (1) CA2660681A1 (https=)
CL (1) CL2007002404A1 (https=)
CO (1) CO6150193A2 (https=)
CR (1) CR10590A (https=)
DK (1) DK2056874T3 (https=)
ES (2) ES2546066T3 (https=)
IL (2) IL196810A0 (https=)
MA (1) MA30654B1 (https=)
MX (1) MX2009001715A (https=)
MY (1) MY150756A (https=)
NO (1) NO20090450L (https=)
NZ (1) NZ574580A (https=)
PE (1) PE20080911A1 (https=)
PL (1) PL2056874T3 (https=)
RU (1) RU2528884C2 (https=)
SG (1) SG174090A1 (https=)
SI (1) SI2056874T1 (https=)
TW (2) TW200825106A (https=)
WO (1) WO2008022746A1 (https=)
ZA (1) ZA200901200B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2709742C2 (ru) * 2014-10-10 2019-12-19 МЕДИММЬЮН, ЭлЭлСи Гуманизированные антитела к ox40 и способы их применения

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130056201A (ko) * 2000-05-19 2013-05-29 제넨테크, 인크. ＥｒｂＢ 길항제에 의한 암 치료요법에 대한 효과적인 반응의 가능성을 개선시키기 위한 유전자 검출 분석
KR20140032004A (ko) 2004-07-22 2014-03-13 제넨테크, 인크. Ｈｅｒ２ 항체 조성물
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
JP2008523073A (ja) * 2004-12-07 2008-07-03 ジェネンテック・インコーポレーテッド Ｈｅｒ阻害剤を用いた治療のための患者の選択
CA2592177A1 (en) 2005-01-21 2006-07-27 Genentech, Inc. Fixed dosing of her antibodies
EP1850874B1 (en) 2005-02-23 2013-10-16 Genentech, Inc. Extending time to disease progression or survival in ovarian cancer patients using pertuzumab
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
DK2056874T3 (da) * 2006-08-21 2012-10-15 Hoffmann La Roche Tumorterapi med et anti-vegf-antistof
MX2009008981A (es) 2007-03-02 2009-09-02 Genentech Inc Prediccion de respuesta a un inhibidor her.
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
CN114805583A (zh) 2010-05-27 2022-07-29 根马布股份公司 针对her2的单克隆抗体
JP6082344B2 (ja) 2010-05-27 2017-02-15 ゲンマブ エー／エス Ｈｅｒ２エピトープに対するモノクローナル抗体
JP5963005B2 (ja) * 2010-07-19 2016-08-03 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 膵臓癌の治療のためのベバシズマブ組合せ療法のための血漿バイオマーカー
NZ607337A (en) * 2010-08-20 2015-06-26 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3)
CA2832389A1 (en) 2011-04-20 2012-10-26 Genmab A/S Bispecific antibodies against her2 and cd3
WO2013055874A2 (en) 2011-10-14 2013-04-18 Genentech, Inc. Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab
KR20140094594A (ko) * 2011-12-05 2014-07-30 에프. 호프만-라 로슈 아게 유방암 치료를 위한 베바시주맙 병용 치료에 대한 혈장 바이오마커
WO2013148159A1 (en) * 2012-03-30 2013-10-03 Fibrogen Inc Therapeutic methods for peritoneal carcinomatosis
RU2019115089A (ru) 2013-04-16 2019-06-11 Дженентек, Инк. Варианты пертузумаба и их аналитическая характеристика
JP2017513901A (ja) 2014-04-25 2017-06-01 ジェネンテック， インコーポレイテッド トラスツズマブ−ｍｃｃ−ｄｍ１及びペルツズマブにより早期の乳癌を処置する方法
US11406715B2 (en) 2015-05-30 2022-08-09 Genentech, Inc. Methods of treating HER2-positive metastatic breast cancer
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
CN106729743B (zh) 2015-11-23 2021-09-21 四川科伦博泰生物医药股份有限公司 抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用
TWI734775B (zh) * 2016-04-26 2021-08-01 美商美國泰福生技股份有限公司 細胞培養基
AU2017387909A1 (en) 2016-12-28 2019-06-27 Genentech, Inc. Treatment of advanced HER2 expressing cancer
SG11201905622VA (en) 2017-01-17 2019-08-27 Genentech Inc Subcutaneous her2 antibody formulations
US11077189B2 (en) 2017-03-02 2021-08-03 Genentech Inc. Adjuvant treatment of HER2-positive breast cancer
EP3615695A1 (en) 2017-04-24 2020-03-04 Genentech, Inc. Erbb2/her2 mutations in the transmebrane or juxtamembrane domain
AU2020456731A1 (en) 2020-06-29 2023-01-05 F. Hoffmann-La Roche Ag Pertuzumab plus trastuzumab fixed dose combination
US20230330094A1 (en) * 2020-09-04 2023-10-19 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Combination compositions and methods for treating cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030232323A1 (en) * 2001-11-13 2003-12-18 Wyeth Agents that modulate immune cell activation and methods of use thereof
WO2006133396A2 (en) * 2005-06-08 2006-12-14 Dana-Farber Cancer Institute Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1) pathway

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
BR9207175A (pt) 1992-10-28 1995-12-12 Genentech Inc Composição contendo antagonista de fator de crescimento de célula endotelial vascular sequência aminoácida de anticorpo monoclonal polipeptídeo e método de tratamento de tumor em mamífero
US6071935A (en) 1996-06-27 2000-06-06 Pfizer Inc. Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use as farnesyl protein transferase inhibitors
CN101412758A (zh) 1996-10-18 2009-04-22 基因技术股份有限公司 抗ErbB2抗体
JP3957765B2 (ja) 1997-04-07 2007-08-15 ジェネンテク・インコーポレイテッド 抗ｖｅｇｆ抗体
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
EP2338915A3 (en) 1997-04-07 2011-10-12 Genentech, Inc. Anti-VEGF antibodies
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
JPH11236333A (ja) 1997-12-30 1999-08-31 Pfizer Prod Inc 抗ガン剤として有用なイミダゾリン−４−オン誘導体
KR20010071271A (ko) 1998-05-15 2001-07-28 존 비. 랜디스 방사선 및 성장 인자 수용체 티로신 키나아제 억제제에의한 사람 종양의 치료법
TR200101343T2 (tr) 1998-08-27 2001-09-21 Pfizer Products Inc. Kansere karşı kullanılan maddeler olarak alkinil-ikame edilmiş kinolin-2-on türevleri
DE69923849T2 (de) 1998-08-27 2006-01-12 Pfizer Products Inc., Groton Quinolin-2-on-derivate verwendbar als antikrebsmittel
AU1728800A (en) 1998-11-18 2000-06-05 Genentech Inc. Antibody variants with higher binding affinity compared to parent antibodies
EP1006113A1 (en) 1998-12-02 2000-06-07 Pfizer Products Inc. Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use to inhibit abnormal cell growth
WO2000035956A1 (fr) 1998-12-16 2000-06-22 Kyowa Hakko Kogyo Co., Ltd. Anticorps monoclonal anti-vegf humain
SK11002001A3 (sk) 1999-02-11 2002-05-09 Pfizer Products Inc. Heteroarylom substituované chinolin-2-ónové deriváty použiteľné ako protinádorové prostriedky
US6586447B1 (en) 1999-04-01 2003-07-01 Pfizer Inc 3,3-disubstituted-oxindole derivatives useful as anticancer agents
JP5623681B2 (ja) 1999-05-14 2014-11-12 ジェネンテック， インコーポレイテッド 抗−ＥｒｂＢ２抗体による治療
US6949245B1 (en) * 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
IL147017A0 (en) 1999-06-25 2002-08-14 Genentech Inc TREATING PROSTATE CANCER WITH ANTI-ErbB2 ANTIBODIES
CA2376596C (en) 1999-06-25 2009-10-06 Genentech, Inc. Humanized anti-erbb2 antibodies and treatment with anti-erbb2 antibodies
PT1106612E (pt) 1999-11-30 2004-06-30 Pfizer Prod Inc Derivados de quinolina uteis para inibir a farnesil-proteina-transferase
UA75055C2 (uk) 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
HN2000000266A (es) 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
US20060036086A1 (en) 2002-03-12 2006-02-16 Jain Rakesh K Use of signal transduction inhibitors and combination therapies for the prevention or treatment of cancer and angiogenesis related diseases
US7435797B2 (en) 2002-04-10 2008-10-14 Genentech, Inc. Anti-HER2 antibody variants
US20040243207A1 (en) 2003-05-30 2004-12-02 Olson Donald R. Medical implant systems
MXPA05012723A (es) 2003-05-30 2006-02-08 Genentech Inc Tratamiento con anticuerpos anti-vgf.
US20050106667A1 (en) * 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
CA2534055A1 (en) 2003-08-01 2005-02-10 Genentech, Inc. Antibody cdr polypeptide sequences with restricted diversity
KR100956913B1 (ko) 2003-12-19 2010-05-11 제넨테크, 인크. 치료제로서 유용한 일가 항체 단편
EP1789446A2 (en) * 2004-09-02 2007-05-30 Genentech, Inc. Heteromultimeric molecules
BRPI0515670A (pt) * 2004-10-04 2008-07-29 Genentech Inc anticorpos isolados e método de tratamento de uma doença associada com descontrole da sinalização do hgf/c-met
TW200812615A (en) * 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
DK2056874T3 (da) * 2006-08-21 2012-10-15 Hoffmann La Roche Tumorterapi med et anti-vegf-antistof
JP2013103182A (ja) * 2011-11-15 2013-05-30 Toray Ind Inc スパイラル型流体分離素子およびその製造方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030232323A1 (en) * 2001-11-13 2003-12-18 Wyeth Agents that modulate immune cell activation and methods of use thereof
WO2006133396A2 (en) * 2005-06-08 2006-12-14 Dana-Farber Cancer Institute Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1) pathway

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TERRAZAS L.I. et al. Role of the programmed Death-1 pathway in the suppressive activity of alternatively activated macrophages in experimental cysticercosis.//Int J Parasitol. 2005 Nov;35(13):1349-58.- реферат. Найдено из Интернета [он-лайн] на сайте 11.02.2014 http://www.ncbi.nlm.nih.gov/pubmed/16126211. GENG H. et al. HSP70 vaccine in combination with gene therapy with plasmid DNA encoding sPD-1 overcomes immune resistance and suppresses the progression of pulmonary metastatic melanoma.//Int J Cancer. 2006 Jun 1;118(11):2657-64. Найдено из Интернета [он-лайн] на сайте 11.02.2014 http://www.ncbi.nlm.nih.gov/pubmed/16425224 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2709742C2 (ru) * 2014-10-10 2019-12-19 МЕДИММЬЮН, ЭлЭлСи Гуманизированные антитела к ox40 и способы их применения

Also Published As

Publication number Publication date
SG174090A1 (en) 2011-09-29
EP2441472A1 (en) 2012-04-18
JP2013163687A (ja) 2013-08-22
HK1134441A1 (en) 2010-04-30
AR062419A1 (es) 2008-11-05
KR20090032136A (ko) 2009-03-31
BRPI0715829A2 (pt) 2013-07-23
MX2009001715A (es) 2009-02-25
US20150239969A1 (en) 2015-08-27
AU2007287794A1 (en) 2008-02-28
JP2010501498A (ja) 2010-01-21
RU2009110102A (ru) 2010-09-27
TW200825106A (en) 2008-06-16
PE20080911A1 (es) 2008-08-15
SI2056874T1 (sl) 2012-12-31
NO20090450L (no) 2009-02-27
IL196810A0 (en) 2011-08-01
US20100285010A1 (en) 2010-11-11
NZ574580A (en) 2011-12-22
EP2441472B1 (en) 2015-06-10
CL2007002404A1 (es) 2008-04-18
ES2546066T3 (es) 2015-09-18
CR10590A (es) 2009-03-20
DK2056874T3 (da) 2012-10-15
CO6150193A2 (es) 2010-04-20
AU2007287794B2 (en) 2013-03-28
CN101505792A (zh) 2009-08-12
TW201107346A (en) 2011-03-01
JP2015214582A (ja) 2015-12-03
US20110223159A1 (en) 2011-09-15
CA2660681A1 (en) 2008-02-28
MA30654B1 (fr) 2009-08-03
EP2056874B1 (en) 2012-09-19
IL238045A0 (en) 2015-05-31
ES2392630T3 (es) 2012-12-12
CN101505792B (zh) 2012-10-03
MY150756A (en) 2014-02-28
KR101136763B1 (ko) 2012-04-24
PL2056874T3 (pl) 2013-02-28
US20080050385A1 (en) 2008-02-28
US20180251536A1 (en) 2018-09-06
WO2008022746A1 (en) 2008-02-28
US20130183292A1 (en) 2013-07-18
EP2056874A1 (en) 2009-05-13
ZA200901200B (en) 2013-08-28

Similar Documents

Publication Publication Date Title
RU2528884C2 (ru) Лечение опухолей с помощью антитела к vegf
RU2538664C2 (ru) Терапия опухолей с использованием антитела к сосудистому эндотелиальному фактору роста и антитела к рецептуру типа 2 человеческого эпителиального фактора роста
US20080102069A1 (en) Tumor therapy with a combination of anti-her2 antibodies
AU2007229008B2 (en) Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
HK1134441B (en) Tumor therapy with an anti-vegf antibody

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20190818